Skip to main content
. 2012 Dec 20;7(12):e52450. doi: 10.1371/journal.pone.0052450

Figure 3. Anti-Dll4 treatment perturbs hematopoiesis following irradiation.

Figure 3

(A) Flow cytometric analysis of the percentage of myeloid (CD11b+) cells, T lymphocytes (CD3+ cells), and B lymphocytes (B220+) in the BM and PB, revealing an increase in both myeloid BM and PB content and a decrease in T and B lymphocyte BM content in anti-Dll4 treated mice. (B) Flow cytometric analysis of the percentage of stem/progenitor cells, namely HSPCs (Sca1+Flk1−) and EPCs (Sca1+Flk1+), revealing that anti-Dll4 treatment does not significantly affect these populations, notwithstanding the trend (p = 0.07) towards and increase of BM HSPCs. Data are means ± s.e.m. *, p<0.05, **, p = 0.07; data represents one of three experiments in which n = 3. (C) Colony counts from methylcellulose culture of Lin- cord blood-derived cells reveal anti-Dll4 treatment in vitro induces an increased HSPCs potential to differentiate to the myeloid lineage (CFU-G and CFU-M), an effect independent upon anti-Notch1 treatment. Anti-Notch1 treatment, independent of combined anti-Dll4 treatment, induces a decrease in HSPCs potential to differentiate to the erythrocytic lineage (CFU-E), and decreased HSPCs differentiation potential (total colony number). All treatments reduced multipotent HSPCs (CFU-GEMM). Data are means ± s.e.m. *, p<0.05; n = 4.